Related Experiment Video
Updated: Feb 17, 2026
08:13
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
7.6K
Using pharmacokinetics to individualize hemophilia therapy
1Department of Health Research, Methods, Evidence, and Impact, and.
Hematology. American Society of Hematology. Education Program
|December 10, 2017
Summary
Population pharmacokinetics can optimize hemophilia treatment by tailoring factor concentrate dosing to individual patient needs. This approach accounts for variability, improving care beyond average pharmacokinetic profiles.
Area of Science:
- Pharmacology
- Hematology
- Clinical Pharmacokinetics
Background:
- Hemophilia treatment relies on maintaining plasma clotting factor activity above target levels.
- Clinical decisions often use pharmacokinetic measures, but average profiles don't optimize individual patient care due to high variability.
- Individual pharmacokinetic profiles are rarely assessed in routine hemophilia care.
Purpose of the Study:
- To explore the potential of population pharmacokinetics for characterizing factor concentrate pharmacokinetics.
- To enable simplified individual pharmacokinetic profiling and individualized dosing strategies in hemophilia.
- To address the need for tailored hemophilia treatment based on individual pharmacokinetics.
Main Methods:
- Utilizing population pharmacokinetic modeling to characterize factor concentrate behavior.
- Incorporating determinants of interpatient variability into models.
- Reducing the need for extensive postinfusion plasma sampling through advanced modeling.
Main Results:
- Population pharmacokinetics offer precise characterization of factor concentrate pharmacokinetics.
- This approach facilitates simplified individual pharmacokinetic profiling and individualized dosing.
- It allows for the incorporation of variability factors, reducing sampling requirements.
Conclusions:
- Population pharmacokinetics offer a theoretical and practical framework for tailoring hemophilia treatment.
- Further prospective studies are needed to validate the clinical impact of individualized pharmacokinetic-based treatment.
- Systematic validation of existing software and concentrate-specific models is required.
Related Concept Videos
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
193
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
193
01:24Dosage Regimen: Individualization
205
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
205
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
18
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
18
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
10
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
10
01:19Nonlinear Pharmacokinetics: Overview
1.2K
Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
Nonlinearity can arise due to the saturation of plasma protein-binding or...
1.2K
01:27Pharmacogenetics of Drug Metabolism: Overview
15
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
15